• Report Adverse Reaction
  • Approved fees Schedules
  • Products Recall And Alert
  • For Stakeholders
  • Submit a Complaint
  • FAQs
  • Submit Advert Application
  • Submit Advert Application
  • Consumer Education

    • Dear Health Care Professional Letter

  • Media
  • Gallery
  • Video
  • News
  • Press Releases

    • Dear Health Care Professional Letter

    Click Topic to Download File
    CANCELLATION OF EMERGENCY USE AUTHORIZATION OF MOLNUPIRAVIR 200MG
    POTENTIALLY LETHAL REACTION TO ANTI-SEIZURE MEDICATIONS (LEVETIRACETAM AND CLOBAZAM)
    IMMEDIATE RECALL OF BELTOCIN AND VERNETOCIN (OXYTOCIN) INJECTIONS 10IUML
    SAFETY ALERT FALSIFIED MERONEM IV ON THE GHANAIAN MARKET
    SAFETY ALERT RECALL OF LUPIN'S QUINAPRIL HYDROCHLORIDE TABLETS
    NEW SAFETY MEASURES ON THE USE OF ISOTRETINOIN
    AMEDIN RECALL LETTER
    FLUOROQUINOLONE ANTIBIOTICS: REMINDER OF MEASURES TO REDUCE THE RISK OF LONG-LASTING, DISABLING AND POTENTIALLY IRREVERSIBLE SIDE EFFECTS
    SAFETY ALERT - SUBSTANDARD PARACETAMOL SUSPENSION RECEIVED FROM REPUBLIC OF LIBERIA
    STRENGTHENED RISK MANAGEMENT FOR SODIUM VALPROATE AND MANDATED CHANGES TO THE PRODUCT INFORMATION
    SAFETY INFORMATION ON THE RISK OF DEVELOPMENT OF ANAPHYLACTIC REACTIONS TO GENERAL ANAESTHESIA WITH NEUROMUSCULAR BLOCKING AGENTS (NMBA)
    SUBSTANDARD (CONTAMINATED) PAEDIATRIC MEDICINES IDENTIFIED IN WHO REGION OF AFRICA
    SAFETY ALERT - RECALL OF PFIZERS ACCUPRIL (QUINAPRIL HYDROCHLORIDE)
    ADDITIONAL RISK MINIMIZATION MEASURES - ENBREL
    ADDITIONAL RISK MINIMIZATION MEASURE - MABTHERA
    SAFETY ALERT - CONTAMINATION OF LOSARTAN ACTIVE SUBSTANCE WITH MUTAGENIC AZIDO IMPURITIES
    SUBSTANDARD AND FALSIFIED CYTOTEC TABLETS IDENTIFIED ON THE GHANAIAN MARKET
    RARE EVENT OF THROMBOSIS AND THROMBOCYTOPENIA FOLLOWING VACCINATION WITH COVID-19 VACCINE ASTRAZENECA
    INFORMATION ON THE RISKS OF VALPROATE USE IN FEMALE PATIENTS AND PREGNANT WOMEN
    USE OF HYDROXYCHLOROQUINE (PLAQUENIL) IN THE CONTEXT OF COVID 19 - RISK OF QT PROLONGATION AND DRUG/DRUG INTERACTIONS
    REPORTING MEDICAL ERRORS
    SUSPECTED ORAL QUININE SULPHATE INDUCED BLEEDING AND INCOMPLETE ABORTION
    SAFETY OF (DEXTRO)PROPOXYPHENE-CONTAINING PRODUCTS
    REVIEW OF THE SAFETY OF METAMIZOLE SODIUM
    REPORTING INCIDENTS OF THERAPEUTIC INEFFECTIVENESS AS ADVERSE EVENTS
    PARACETAMOL AND THE RISK OF RARE BUT SERIOUS SKIN REACTIONS
    OVER-THE-COUNTER COLD AND COUGH PREPARATIONS IN CHILDREN: FOLLOW-UP TO AN EARLIER COMMUNICATION
    DICLOFENAC AND RISK OF CARDIOVASCULAR EVENTS (HEART ATTACK AND STROKE)
    AZITHROMYCIN AND CARDIOVASCULAR RISKS
    ANGIOTENSEN CONVERTING ENZYME INHIBITOR-ASSOCIATED ANGIODEMA
    RARE OCCURRENCES OF A SERIOUS INFECTION OF THE GENITAL AREA WITH SODIUM-GLUCOSE COTRANSPORTER-2(SGLT2) INHIBITORS FOR DIABETES
    HYDROCHLOROTHIAZIDE AND THE RISK OF SKIN CANCER
    UPDATE-SAFETY INFORMATION ON VALSARTAN
    SUSPENSION OF MARKETING AUTHORIZATION FOR CODEINE-CONTAINING COUGH SYRUPS
    POTENTIAL FOR INCREASED LTR WITH CLARITHROMYCIN
    RESTRICTIONS ON THE USE OF CODEINE AS AN ANALGESIC IN CHILDREN AND ADOLESCENTS
    SAFETY OF INJECTABLE GADOLINIUM-BASED CONTRAST AGENTS USED IN MAGNETIC RESONANCE IMAGE (MRI) MACHINES
    POTENTIAL CARCINOGENIC EFFECT OF GENTIAN VIOLET
    POTENTIAL CONTAMINATION OF METFORMIN WITH N-NITROSODIMETHYLAMINE
    SAFETY ALERT ON POTENTIAL CONTAMINATION OF RANITIDINE WITH N-NITROSODIMETHLAMINE
    SEVERE BUT RARE LUNG INFLAMMATION WITH IBRANCE
    RESTRICTIONS ON FLUOROQUINOLONE USE
    RESTRICTIONS TO PREVENT THE USE OF VALPROATE MEDICINES IN WOMEN AND GIRLS OF CHILDBEARING POTENTIAL
    RECALL OF AMLODIPIN/VALSATAN COMBINATION TABLETS
    FOLLOW UP: SUSPENSION OF MARKET AUTHORISATION OF CODEINE-CONTAINING COUGH SYRUPS
    SUSPENSION OF MARKETING AUTHORIZATION FOR ORAL KETOCONAZOLE PRODUCTS
    UPDATE ON SAFETY OF PIOGLITAZONE
    RARE BUT SERIOUS ALLERGIC REACTIONS WITH THE SKIN ANTISEPTIC CHLORHEXIDINE GLUCONATE
    ORAL KETOCONAZOLE AND THE RISK OF SEVERE LIVER INJURY, ADRENAL GLAND PROBLEMS AND HARMFUL DRUG INTERACTIONS
    ASSOCIATION OF IBANDRONIC ACID AND ANAPHYLAXIS (ANAPHYLACTIC REACTION, ANAPHYLACTIC SHOCK)
    BOXED WARNING - EXJADE (DEFERASIROX)

    • THE FDA MISSION

    The FDA exist to ensure the safety, quality and efficacy of human and veterinary drugs, food, biological products, cosmetics, medical devices, household chemical substances and clinical trials, and the control of tobacco products through the enforcement of relevant standards to protect public health.

  • Discover More

    • Subscription Management Centre

    Connect & Get Interactive

  • Disclaimer
  • Site Map
  • Carreers & Job At FDA
  • Send Us a mail
    • Top